NASDAQ:REGN - Regeneron Pharmaceuticals Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
About
FAQ

Consensus Rating: Buy
Consensus Price Target: $656.11
Forecasted Upside: 25.31 %
Number of Analysts: 16
Breakdown:
0 Sell Ratings
4 Hold Ratings
12 Buy Ratings
0 Strong Buy Ratings

^$523.58 As of 06/16/2021 01:00 AM ET

▼ -3.91 (-0.74%)

1 month | 3 months | 12 months

Get New Regeneron Pharmaceuticals Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for REGN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for REGN

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

^$656.11

▲ +25.31% Upside Potential

This price target is based on 16 analysts offering 12 month price targets for Regeneron Pharmaceuticals in the last 3 months. The average price target is $656.11, with a high forecast of $800.00 and a low forecast of $495.00. The average price target represents a 25.31% upside from the last price of $523.58.

Buy

The current consensus among 16 contributing investment analysts is to buy stock in Regeneron Pharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
14 buy ratings
6 hold ratings
0 sell ratings

Ratings as of

12/24/2019

0 strong buy ratings
16 buy ratings
7 hold ratings
0 sell ratings

Ratings as of

3/23/2020

1 strong buy ratings
18 buy ratings
8 hold ratings
0 sell ratings

Ratings as of

6/21/2020

1 strong buy ratings
18 buy ratings
8 hold ratings
0 sell ratings

Ratings as of

9/19/2020

1 strong buy ratings
16 buy ratings
7 hold ratings
0 sell ratings

Ratings as of

12/18/2020

1 strong buy ratings
14 buy ratings
6 hold ratings
0 sell ratings

Ratings as of

3/18/2021

0 strong buy ratings
14 buy ratings
5 hold ratings
0 sell ratings

Ratings as of

5/17/2021

0 strong buy ratings
12 buy ratings
4 hold ratings
0 sell ratings

Ratings as of

6/16/2021

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price	Details
5/7/2021	SVB Leerink	Lower Price Target	Outperform	$657.00 ➝ $641.00	Low	i
5/7/2021	Morgan Stanley	Boost Price Target	Equal Weight	$477.00 ➝ $495.00	Low	i
4/19/2021	Morgan Stanley	Lower Price Target	Equal Weight	$525.00 ➝ $477.00	Low	i
4/13/2021	Robert W. Baird	Reiterated Rating	Hold		Low	i
4/13/2021	Canaccord Genuity	Reiterated Rating	Buy		Low	i
3/26/2021	SVB Leerink	Boost Price Target	Outperform	$655.00 ➝ $657.00	High	i
3/24/2021	Canaccord Genuity	Reiterated Rating	Buy		High	i
2/24/2021	Canaccord Genuity	Reiterated Rating	Buy		Medium	i
2/23/2021	Credit Suisse Group	Boost Price Target	Outperform	$753.00 ➝ $760.00	High	i
2/16/2021	Cantor Fitzgerald	Lower Price Target	Overweight	$696.00 ➝ $656.00	Low	i
2/8/2021	Morgan Stanley	Lower Price Target	Equal Weight	$553.00 ➝ $525.00	Medium	i
2/8/2021	Credit Suisse Group	Lower Price Target	Outperform	$758.00 ➝ $753.00	Medium	i
2/8/2021	Cowen	Lower Price Target	Outperform	$684.00 ➝ $565.00	High	i
2/8/2021	SVB Leerink	Boost Price Target	Outperform	$623.00 ➝ $640.00	High	i
1/25/2021	BMO Capital Markets	Upgrade	Market Perform ➝ Outperform	$630.00	Medium	i
1/19/2021	Morgan Stanley	Boost Price Target	Equal Weight	$527.00 ➝ $553.00	Low	i
1/14/2021	Smith Barney Citigroup	Boost Price Target		$575.00 ➝ $584.00	Low	i
1/14/2021	Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell	Boost Price Target	Buy	$575.00 ➝ $584.00	Low	i
1/13/2021	Benchmark	Upgrade	Hold ➝ Buy	$590.00	Medium	i
1/8/2021	Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell	Upgrade	Neutral ➝ Buy	$635.00 ➝ $575.00	Medium	i
1/8/2021	FIX	Upgrade	Neutral ➝ Buy	$635.00 ➝ $575.00	Medium	i
12/16/2020	Morgan Stanley	Lower Price Target	Equal Weight	$602.00 ➝ $527.00	Low	i
12/16/2020	Credit Suisse Group	Lower Price Target	Outperform	$737.00 ➝ $736.00	Medium	i
11/9/2020	Morgan Stanley	Lower Price Target	Equal Weight	$609.00 ➝ $602.00	High	i
11/6/2020	Truist	Boost Price Target		$750.00 ➝ $770.00	Low	i
11/6/2020	Credit Suisse Group	Lower Price Target	Outperform	$745.00 ➝ $737.00	Low	i
11/6/2020	SVB Leerink	Boost Price Target	Outperform	$650.00 ➝ $653.00	Low	i Rating by Geoff Porges at SVB Leerink LLC
11/6/2020	BMO Capital Markets	Boost Price Target	Market Perform	$626.00 ➝ $630.00	Low	i
10/13/2020	Morgan Stanley	Lower Price Target	Equal Weight	$611.00 ➝ $609.00	Low	i
10/6/2020	SVB Leerink	Boost Price Target	Outperform	$629.00 ➝ $650.00	High	i Rating by Geoff Porges at SVB Leerink LLC
10/5/2020	Cantor Fitzgerald	Upgrade	Neutral ➝ Overweight	$690.00	High	i
10/1/2020	JPMorgan Chase & Co.	Reiterated Rating	Hold		High	i
8/20/2020	Benchmark	Downgrade	Buy ➝ Hold		High	i Rating by Aydin Huseynov at Benchmark Co.
8/7/2020	Credit Suisse Group	Boost Price Target	Outperform	$716.00 ➝ $725.00	Low	i
8/6/2020	Barclays	Boost Price Target		$615.00 ➝ $675.00	Low	i
8/6/2020	Morgan Stanley	Lower Price Target	Equal Weight	$619.00 ➝ $611.00	Low	i
8/6/2020	Oppenheimer	Boost Price Target	Outperform	$675.00 ➝ $725.00	Low	i Rating by Hartaj Singh at Oppenheimer Holdings Inc.
8/6/2020	Citigroup	Boost Price Target	Neutral	$585.00 ➝ $635.00	Low	i
8/6/2020	BMO Capital Markets	Boost Price Target	Outperform	$525.00 ➝ $626.00	Low	i
8/5/2020	The Goldman Sachs Group	Boost Price Target		$700.00 ➝ $800.00	Low	i
8/5/2020	Piper Sandler	Boost Price Target	Overweight	$630.00 ➝ $675.00	High	i
7/20/2020	Credit Suisse Group	Boost Price Target	Outperform	$700.00 ➝ $716.00	High	i
7/15/2020	Morgan Stanley	Boost Price Target	Equal Weight	$555.00 ➝ $619.00	Low	i
7/8/2020	SunTrust Banks	Upgrade	Hold ➝ Buy	$400.00 ➝ $750.00	Low	i
7/8/2020	Canaccord Genuity	Boost Price Target	Buy	$600.00 ➝ $700.00	Low	i
7/1/2020	Oppenheimer	Boost Price Target	Outperform	$625.00 ➝ $675.00	High	i Rating by Hartaj Singh at Oppenheimer Holdings Inc.
6/24/2020	Credit Suisse Group	Boost Price Target	Outperform	$605.00 ➝ $700.00	High	i
6/12/2020	Jefferies Financial Group	Boost Price Target	Buy	$657.00 ➝ $691.00	High	i Rating by Biren Amin at Jefferies Financial Group Inc.
6/2/2020	Jefferies Financial Group	Reiterated Rating	Buy	$657.00	Low	i Rating by Biren Amin at Jefferies Financial Group Inc.
6/2/2020	Cowen	Reiterated Rating	Hold	$584.00	Low	i Rating by Yaron Werber at Cowen Inc
6/2/2020	Oppenheimer	Reiterated Rating	Buy	$625.00	Low	i
6/2/2020	Cantor Fitzgerald	Boost Price Target	Neutral	$400.00 ➝ $624.00	Low	i
5/28/2020	Barclays	Boost Price Target		$530.00 ➝ $615.00	High	i
5/27/2020	Cfra	Lower Price Target	Hold	$557.00 ➝ $549.00	Low	i
5/27/2020	SVB Leerink	Boost Price Target	Outperform	$622.00 ➝ $625.00	High	i Rating by Geoff Porges at SVB Leerink LLC
5/26/2020	SVB Leerink	Reiterated Rating	Buy	$622.00	Low	i Rating by Geoff Porges at SVB Leerink LLC
5/26/2020	Wells Fargo & Company	Upgrade	Equal Weight ➝ Overweight	$559.00 ➝ $734.00	High	i
5/6/2020	Robert W. Baird	Boost Price Target	Neutral ➝ Neutral	$487.00 ➝ $510.00	High	i
5/6/2020	Canaccord Genuity	Boost Price Target	Buy	$575.00 ➝ $630.00	High	i
5/6/2020	BMO Capital Markets	Boost Price Target	Market Perform	$466.00 ➝ $525.00	High	i
5/6/2020	Royal Bank of Canada	Lower Price Target		$533.00 ➝ $524.00	Medium	i
5/6/2020	Piper Sandler	Boost Price Target		$550.00 ➝ $600.00	Low	i
5/6/2020	Morgan Stanley	Boost Price Target	Equal Weight	$409.00 ➝ $555.00	Medium	i
5/6/2020	Oppenheimer	Boost Price Target	Outperform	$525.00 ➝ $625.00	High	i
5/6/2020	Credit Suisse Group	Boost Price Target	Outperform	$596.00 ➝ $605.00	High	i Rating by Evan Seigerman at Credit Suisse Group AG
5/6/2020	The Goldman Sachs Group	Boost Price Target	Conviction-Buy	$636.00 ➝ $700.00	High	i
5/6/2020	SVB Leerink	Boost Price Target	Outperform	$604.00 ➝ $622.00	High	i
5/1/2020	Piper Sandler	Reiterated Rating	Overweight		Low	i
4/28/2020	Canaccord Genuity	Boost Price Target	Buy	$550.00 ➝ $575.00	Medium	i
4/28/2020	Citigroup	Downgrade	Buy ➝ Neutral	$540.00 ➝ $575.00	High	i
4/19/2020	Benchmark	Initiated Coverage	Hold		Low	i Rating by Aydin Huseynov at Benchmark Co.
4/17/2020	BMO Capital Markets	Boost Price Target	Market Perform	$379.00 ➝ $466.00	High	i
4/17/2020	Benchmark	Upgrade	Hold ➝ Buy	$655.00	High	i
4/15/2020	Morgan Stanley	Lower Price Target	Equal Weight	$410.00 ➝ $409.00	Medium	i
4/15/2020	JPMorgan Chase & Co.	Boost Price Target	Neutral	$375.00 ➝ $429.00	Medium	i
4/8/2020	Benchmark	Initiated Coverage	Hold		Medium	i
4/7/2020	SVB Leerink	Boost Price Target	Outperform	$600.00 ➝ $604.00	Medium	i
4/6/2020	Wells Fargo & Company	Boost Price Target	Equal Weight	$370.00 ➝ $435.00	Low	i
3/31/2020	Wolfe Research	Initiated Coverage	Market Perform	$455.00	High	i
3/12/2020	Argus	Boost Price Target	Buy	$430.00 ➝ $540.00	High	i Rating by Jasper Hellweg at Argus
3/11/2020	Oppenheimer	Boost Price Target	Outperform	$450.00 ➝ $525.00	Medium	i
3/4/2020	Cfra	Boost Price Target	Buy ➝ Hold	$460.00 ➝ $487.00	High	i
3/4/2020	Piper Sandler	Boost Price Target		$435.00 ➝ $500.00	High	i
2/28/2020	Cowen	Boost Price Target	Market Perform	$386.00 ➝ $495.00	High	i Rating by Yaron Werber at Cowen Inc
2/28/2020	Citigroup	Boost Price Target	Buy	$420.00 ➝ $540.00	High	i
2/27/2020	Barclays	Initiated Coverage	Overweight	$530.00	High	i
2/26/2020	Sanford C. Bernstein	Upgrade	Market Perform ➝ Outperform	$500.00	Medium	i
2/26/2020	Credit Suisse Group	Boost Price Target	Top Pick ➝ Outperform	$420.00 ➝ $510.00	High	i Rating by Evan Seigerman at Credit Suisse Group AG
2/26/2020	Robert W. Baird	Downgrade	Outperform ➝ Neutral	$410.00	High	i
2/26/2020	Canaccord Genuity	Upgrade	Hold ➝ Buy	$409.00 ➝ $550.00	High	i Rating by John Newman at Canaccord Genuity
2/25/2020	Jefferies Financial Group	Upgrade	Hold ➝ Buy	$355.00 ➝ $492.00	High	i
2/24/2020	Evercore ISI	Upgrade	In-Line ➝ Outperform	$500.00	High	i Rating by Joshua Schimmer at Evercore ISI
2/11/2020	Argus	Upgrade	Hold ➝ Buy	$430.00	Medium	i
2/7/2020	Evercore ISI	Initiated Coverage	Hold	$400.00	Low	i Rating by Joshua Schimmer at Evercore ISI
2/7/2020	Morgan Stanley	Lower Price Target	Equal Weight	$411.00 ➝ $410.00	Low	i
2/7/2020	SunTrust Banks	Boost Price Target	Hold	$400.00	High	i
1/22/2020	Oppenheimer	Boost Price Target	Outperform	$430.00 ➝ $450.00	Low	i
1/17/2020	Morgan Stanley	Boost Price Target	Equal Weight	$387.00 ➝ $411.00	Low	i
1/14/2020	JPMorgan Chase & Co.	Reiterated Rating	Hold		High	i
12/23/2019	Raymond James	Initiated Coverage	Market Perform		N/A	i Rating by Dane Leone at Raymond James
12/13/2019	Credit Suisse Group	Upgrade	Neutral ➝ Outperform	$400.00	Low	i Rating by Evan Seigerman at Credit Suisse Group AG
12/9/2019	Credit Suisse Group	Upgrade	Neutral ➝ Outperform	$400.00	Low	i
11/12/2019	SunTrust Banks	Initiated Coverage	Hold	$360.00	Medium	i
11/11/2019	Evercore ISI	Reiterated Rating	Buy	$395.00	Low	i
11/6/2019	Citigroup	Upgrade	Neutral ➝ Buy	$340.00 ➝ $420.00	Low	i
11/6/2019	Oppenheimer	Lower Price Target		$480.00 ➝ $430.00	Low	i
11/6/2019	BMO Capital Markets	Boost Price Target	Market Perform	$344.00 ➝ $358.00	Medium	i Rating by Matthew Luchini at BMO Capital Markets
11/6/2019	JPMorgan Chase & Co.	Reiterated Rating	Hold	$375.00	Medium	i Rating by Cory Kasimov at JPMorgan Chase & Co.
11/6/2019	Credit Suisse Group	Boost Price Target	Neutral ➝ Neutral	$310.00 ➝ $340.00	Medium	i
10/16/2019	Bank of America	Initiated Coverage	Neutral	$325.00	Low	i
10/9/2019	Canaccord Genuity	Lower Price Target	Hold	$353.00 ➝ $320.00	Medium	i
10/8/2019	Cowen	Set Price Target	Hold	$349.00	Low	i Rating by Yaron Werber at Cowen Inc
10/8/2019	Piper Jaffray Companies	Set Price Target	Buy	$435.00	Low	i Rating by Christopher Raymond at Piper Jaffray Companies
10/8/2019	BMO Capital Markets	Set Price Target	Hold	$344.00	Low	i Rating by Matthew Luchini at BMO Capital Markets
9/23/2019	Guggenheim	Upgrade	Neutral ➝ Buy	$355.00 ➝ $403.00	Low	i
8/7/2019	Robert W. Baird	Upgrade	Neutral ➝ Outperform	$410.00	Low	i
8/7/2019	Credit Suisse Group	Lower Price Target	Neutral	$333.00 ➝ $325.00	Low	i
8/7/2019	BMO Capital Markets	Lower Price Target	Market Perform	$344.00	Low	i Rating by Matthew Luchini at BMO Capital Markets
7/29/2019	Cowen	Reiterated Rating	Hold	$353.00	Medium	i
6/21/2019	JPMorgan Chase & Co.	Reiterated Rating	Hold		Low	i Rating by Cory Kasimov at JPMorgan Chase & Co.
6/18/2019	Argus	Downgrade	Buy ➝ Hold		High	i
6/14/2019	JPMorgan Chase & Co.	Reiterated Rating	Hold		Low	i Rating by Cory Kasimov at JPMorgan Chase & Co.
6/11/2019	SVB Leerink	Set Price Target	Buy	$453.00	Low	i Rating by Geoff Porges at SVB Leerink LLC
5/23/2019	Citigroup	Lower Price Target	Neutral ➝ Neutral	$396.00 ➝ $340.00	Low	i
5/20/2019	Credit Suisse Group	Initiated Coverage	Neutral	$336.00	High	i
5/13/2019	Cantor Fitzgerald	Lower Price Target	Neutral	$441.00 ➝ $405.00	Medium	i
5/8/2019	BMO Capital Markets	Lower Price Target	Positive ➝ Market Perform	$412.00 ➝ $375.00	Medium	i
5/8/2019	Morgan Stanley	Lower Price Target	Equal Weight	$420.00 ➝ $389.00	Medium	i
5/8/2019	Canaccord Genuity	Reiterated Rating	Hold ➝ Hold	$408.00 ➝ $353.00	High	i
5/8/2019	UBS Group	Lower Price Target	Buy	$480.00 ➝ $440.00	Medium	i
5/7/2019	Piper Jaffray Companies	Reiterated Rating	Overweight	$435.00	Medium	i
5/7/2019	Cowen	Reiterated Rating	Hold	$353.00	Medium	i
4/17/2019	Jefferies Financial Group	Lower Price Target	Hold	$376.00 ➝ $343.00	High	i
2/26/2019	Piper Jaffray Companies	Boost Price Target	Overweight	$487.00	Medium	i
2/22/2019	Guggenheim	Downgrade	Buy ➝ Neutral	$466.00 ➝ $425.00	Low	i Rating by Adnan Butt at Guggenheim
2/7/2019	Oppenheimer	Boost Price Target	Outperform	$440.00 ➝ $480.00	Low	i Rating by Hartaj Singh at Oppenheimer Holdings Inc.
2/7/2019	BMO Capital Markets	Boost Price Target	Market Perform	$412.00	Low	i
2/6/2019	Cantor Fitzgerald	Reiterated Rating	Hold	$441.00	High	i
1/7/2019	Cowen	Reiterated Rating	Hold	$385.00	Low	i
1/4/2019	Guggenheim	Upgrade	Neutral ➝ Buy	$461.00	High	i
12/13/2018	The Goldman Sachs Group	Upgrade	Neutral ➝ Conviction-Buy		Low	i
12/7/2018	SVB Leerink	Set Price Target	Buy	$473.00 ➝ $483.00	Low	i
12/2/2018	Oppenheimer	Set Price Target	Buy	$440.00	High	i Rating by Hartaj Singh at Oppenheimer Holdings Inc.
11/13/2018	Argus	Reiterated Rating	Buy		Low	i
11/7/2018	JPMorgan Chase & Co.	Set Price Target	Hold	$405.00	Medium	i Rating by Cory Kasimov at JPMorgan Chase & Co.
11/6/2018	Cowen	Reiterated Rating	Hold	$385.00	Medium	i
10/22/2018	Cowen	Reiterated Rating	Hold	$385.00	Medium	i
10/22/2018	Cantor Fitzgerald	Boost Price Target	Neutral	$441.00	Low	i
10/22/2018	JPMorgan Chase & Co.	Set Price Target	Hold	$405.00	Low	i Rating by Cory Kasimov at JPMorgan Chase & Co.
10/11/2018	Morgan Stanley	Boost Price Target	Equal Weight	$409.00 ➝ $412.00	High	i
10/11/2018	Canaccord Genuity	Boost Price Target	Hold	$390.00 ➝ $410.00	High	i
10/2/2018	JPMorgan Chase & Co.	Reiterated Rating	Hold		Medium	i
10/1/2018	SVB Leerink	Boost Price Target	Outperform	$506.00 ➝ $512.00	High	i Rating by Geoff Porges at SVB Leerink LLC
10/1/2018	Cantor Fitzgerald	Initiated Coverage	Neutral ➝ Neutral	$415.00	High	i
8/16/2018	Cowen	Reiterated Rating	Hold	$385.00	Low	i
8/6/2018	Barclays	Boost Price Target	Underweight ➝ Underweight	$290.00 ➝ $305.00	Low	i Rating by Geoff Meacham at Barclays PLC
8/3/2018	Canaccord Genuity	Boost Price Target	Hold ➝ Hold	$304.00 ➝ $390.00	Low	i
8/3/2018	SunTrust Banks	Reiterated Rating	Hold	$400.00	Low	i Rating by Yatin Suneja at SunTrust Banks, Inc.
8/3/2018	Morgan Stanley	Boost Price Target	Equal Weight ➝ Equal Weight	$396.00 ➝ $409.00	Low	i
8/3/2018	Robert W. Baird	Downgrade	Outperform ➝ Neutral		Low	i
8/2/2018	BMO Capital Markets	Set Price Target	Hold	$388.00	Low	i Rating by Matthew Luchini at BMO Capital Markets
7/24/2018	Jefferies Financial Group	Reiterated Rating	Hold	$340.00	Medium	i
7/19/2018	Canaccord Genuity	Reiterated Rating	$367.74	$304.00	Low	i
7/16/2018	Argus	Boost Price Target	Buy ➝ Buy	$383.00 ➝ $415.00	Low	i
7/13/2018	Morgan Stanley	Boost Price Target	Equal Weight	$370.00 ➝ $396.00	Low	i
7/2/2018	SunTrust Banks	Set Price Target	Hold	$344.00	Low	i Rating by Yatin Suneja at SunTrust Banks, Inc.
6/27/2018	Oppenheimer	Upgrade	Market Perform ➝ Outperform	$325.00	High	i
6/27/2018	UBS Group	Upgrade	Market Perform ➝ Outperform		High	i
5/23/2018	Barclays	Set Price Target	Sell	$290.00	Low	i Rating by Geoff Meacham at Barclays PLC
5/7/2018	Royal Bank of Canada	Lower Price Target	Sector Perform	$342.00	Low	i
5/5/2018	Credit Suisse Group	Set Price Target	Buy	$420.00	Low	i Rating by Alethia Young at Credit Suisse Group AG
5/4/2018	Morgan Stanley	Lower Price Target	Equal Weight ➝ Equal Weight	$400.00 ➝ $370.00	Low	i
5/4/2018	Canaccord Genuity	Lower Price Target	Hold ➝ Hold	$356.00 ➝ $304.00	Low	i
5/4/2018	SVB Leerink	Set Price Target	Buy	$502.00 ➝ $435.00	Low	i
5/4/2018	BMO Capital Markets	Set Price Target	Market Perform ➝ Hold	$398.00 ➝ $361.00	Low	i Rating by Matthew Luchini at BMO Capital Markets
5/4/2018	Cowen	Reiterated Rating	Outperform	$400.00 ➝ $350.00	Low	i
5/4/2018	SunTrust Banks	Lower Price Target	Hold	$344.00	Low	i Rating by Yatin Suneja at SunTrust Banks, Inc.
5/3/2018	Barclays	Set Price Target	Sell	$290.00	Low	i Rating by Geoff Meacham at Barclays PLC
5/1/2018	Guggenheim	Downgrade	Buy ➝ Neutral		Low	i Rating by Adnan Butt at Guggenheim
4/27/2018	Credit Suisse Group	Set Price Target	Buy	$420.00	High	i Rating by Alethia Young at Credit Suisse Group AG
4/27/2018	Cowen	Reiterated Rating	Hold	$400.00	Low	i
4/17/2018	Credit Suisse Group	Lower Price Target	Buy	$440.00 ➝ $420.00	Low	i Rating by Alethia Young at Credit Suisse Group AG
4/9/2018	Raymond James	Reiterated Rating	Outperform ➝ Market Perform		Low	i
4/9/2018	UBS Group	Downgrade	Outperform ➝ Market Perform		Low	i
3/13/2018	BTIG Research	Reiterated Rating	Hold		Medium	i
3/13/2018	Deutsche Bank Aktiengesellschaft	Set Price Target	Hold	$367.00	Medium	i Rating by Navin Jacob at Deutsche Bank Aktiengesellschaft
2/21/2018	Canaccord Genuity	Downgrade	Buy ➝ Hold	$522.00 ➝ $356.00	Medium	i
2/13/2018	BTIG Research	Reiterated Rating	Hold		High	i
2/9/2018	SunTrust Banks	Set Price Target	Hold	$430.00	Low	i Rating by Yatin Suneja at SunTrust Banks, Inc.
2/9/2018	Morgan Stanley	Boost Price Target	Equal Weight ➝ Equal Weight	$401.00 ➝ $415.00	High	i
2/9/2018	SVB Leerink	Lower Price Target	Outperform ➝ Outperform	$568.00 ➝ $502.00	High	i
2/9/2018	Robert W. Baird	Upgrade	Neutral ➝ Outperform		High	i
2/9/2018	Guggenheim	Set Price Target	Buy	$530.00	High	i
2/8/2018	Jefferies Financial Group	Reiterated Rating	Neutral ➝ Hold	$380.00	High	i
2/8/2018	BTIG Research	Downgrade	Buy ➝ Neutral	$480.00	High	i
2/8/2018	BMO Capital Markets	Boost Price Target	Market Perform ➝ Market Perform	$398.00 ➝ $444.00	Low	i Rating by Matthew Luchini at BMO Capital Markets
2/7/2018	Credit Suisse Group	Set Price Target	Buy	$440.00	High	i Rating by Alethia Young at Credit Suisse Group AG
2/7/2018	Cowen	Reiterated Rating	Hold	$450.00	High	i
2/7/2018	Canaccord Genuity	Reiterated Rating	Buy	$522.00	High	i Rating by John Newman at Canaccord Genuity
2/2/2018	Jefferies Financial Group	Reiterated Rating	Hold	$421.00	Medium	i
1/24/2018	JPMorgan Chase & Co.	Boost Price Target	Neutral ➝ Neutral	$455.00 ➝ $457.00	Low	i Rating by Cory Kasimov at JPMorgan Chase & Co.
1/9/2018	Citigroup	Reiterated Rating	Neutral ➝ Neutral	$380.00 ➝ $388.00	High	i
12/28/2017	Argus	Lower Price Target	Positive ➝ Buy	$540.00 ➝ $470.00	Low	i
12/14/2017	Royal Bank of Canada	Reiterated Rating	Hold	$430.00	Low	i
12/12/2017	Deutsche Bank Aktiengesellschaft	Initiated Coverage	Hold	$397.00	Medium	i
12/1/2017	Citigroup	Downgrade	Buy ➝ Neutral	$480.00 ➝ $380.00	High	i
11/28/2017	JPMorgan Chase & Co.	Reiterated Rating	Hold		Medium	i Rating by Cory Kasimov at JPMorgan Chase & Co.
11/28/2017	BTIG Research	Lower Price Target	Buy ➝ Buy	$520.00 ➝ $480.00	Low	i
11/27/2017	BMO Capital Markets	Set Price Target	Hold	$444.00	High	i Rating by Matthew Luchini at BMO Capital Markets
11/22/2017	BTIG Research	Reiterated Rating	Buy	$520.00	Low	i
11/16/2017	Evercore ISI	Lower Price Target	Outperform	$605.00 ➝ $445.00	N/A	i Rating by Josh Schimmer at Evercore ISI
11/13/2017	Piper Jaffray Companies	Reiterated Rating	Buy	$540.00	N/A	i Rating by Edward Tenthoff at Piper Jaffray Companies
11/9/2017	Morgan Stanley	Lower Price Target	Equal Weight	$490.00 ➝ $463.00	N/A	i
11/9/2017	Royal Bank of Canada	Reiterated Rating	Sector Perform ➝ Sector Perform	$473.00 ➝ $425.00	N/A	i
11/9/2017	BMO Capital Markets	Lower Price Target	Market Perform	$491.00 ➝ $479.00	N/A	i Rating by Matthew Luchini at BMO Capital Markets
11/9/2017	Citigroup	Reiterated Rating	Buy	$480.00	N/A	i
11/3/2017	Robert W. Baird	Upgrade	Underperform ➝ Neutral		N/A	i
10/31/2017	JPMorgan Chase & Co.	Reiterated Rating	Hold		N/A	i Rating by Cory Kasimov at JPMorgan Chase & Co.
10/23/2017	Guggenheim	Reiterated Rating	Buy ➝ Buy	$540.00	N/A	i
10/20/2017	Barclays	Downgrade	Equal Weight ➝ Underweight	$450.00 ➝ $395.00	N/A	i
10/16/2017	JPMorgan Chase & Co.	Reiterated Rating	Hold		N/A	i Rating by Cory Kasimov at JPMorgan Chase & Co.
10/16/2017	Canaccord Genuity	Reiterated Rating	Buy		N/A	i Rating by John Newman at Canaccord Genuity
10/6/2017	Morgan Stanley	Reiterated Rating	Equal Weight	$450.00 ➝ $490.00	N/A	i
10/6/2017	Jefferies Financial Group	Reiterated Rating	Hold	$471.00 ➝ $500.00	N/A	i
10/2/2017	SunTrust Banks	Reiterated Rating	Hold	$435.00	Medium	i
9/29/2017	Piper Jaffray Companies	Reiterated Rating	Overweight ➝ Overweight	$540.00	High	i Rating by Edward Tenthoff at Piper Jaffray Companies
9/27/2017	Oppenheimer	Reiterated Rating	Hold		Low	i Rating by Hartaj Singh at Oppenheimer Holdings Inc.
9/21/2017	UBS Group	Lower Price Target	Buy	$535.00 ➝ $500.00	Medium	i Rating by Carter Gould at UBS Group AG
9/14/2017	Royal Bank of Canada	Initiated Coverage	Sector Perform ➝ Sector Perform	$475.00	Medium	i
9/11/2017	Canaccord Genuity	Reiterated Rating	Buy	$522.00	Low	i Rating by John Newman at Canaccord Genuity
9/11/2017	Credit Suisse Group	Reiterated Rating	Buy	$485.00	Low	i Rating by Alethia Young at Credit Suisse Group AG
9/8/2017	Robert W. Baird	Reiterated Rating	Sell	$408.00	Low	i
9/7/2017	Citigroup	Reiterated Rating	Buy	$575.00	Low	i
9/6/2017	Raymond James	Reiterated Rating	Outperform ➝ Outperform	$566.00	Low	i
8/23/2017	Morgan Stanley	Reiterated Rating	Equal Weight	$450.00	Low	i
8/16/2017	Evercore ISI	Initiated Coverage	Outperform ➝ Outperform	$605.00	Medium	i
8/15/2017	JPMorgan Chase & Co.	Reiterated Rating	Hold		Low	i Rating by Cory Kasimov at JPMorgan Chase & Co.
8/15/2017	SVB Leerink	Reiterated Rating	Outperform ➝ Positive	$580.00 ➝ $552.00	Low	i Rating by Geoff Porges at SVB Leerink LLC
8/14/2017	Canaccord Genuity	Set Price Target	Buy	$522.00	Low	i Rating by John Newman at Canaccord Genuity
8/9/2017	Jefferies Financial Group	Reiterated Rating	Hold	$418.00 ➝ $471.00	Low	i
8/9/2017	The Goldman Sachs Group	Reiterated Rating	Neutral	$469.00 ➝ $472.00	Low	i
8/9/2017	JPMorgan Chase & Co.	Reiterated Rating	Hold	$427.00 ➝ $455.00	Low	i Rating by Cory Kasimov at JPMorgan Chase & Co.
8/9/2017	SVB Leerink	Reiterated Rating	Outperform	$573.00 ➝ $580.00	Low	i Rating by Geoff Porges at SVB Leerink LLC
8/8/2017	Robert W. Baird	Downgrade	Neutral ➝ Underperform	$408.00	Low	i
8/4/2017	UBS Group	Reiterated Rating	Buy ➝ Buy	$489.00 ➝ $535.00	Low	i Rating by Carter Gould at UBS Group AG
8/4/2017	Citigroup	Boost Price Target	Buy	$555.00 ➝ $575.00	Low	i
8/3/2017	BMO Capital Markets	Set Price Target	Hold	$491.00	Low	i Rating by Matthew Luchini at BMO Capital Markets
8/3/2017	Canaccord Genuity	Set Price Target	Buy	$522.00	Low	i Rating by John Newman at Canaccord Genuity
8/3/2017	JPMorgan Chase & Co.	Reiterated Rating	Hold		Low	i Rating by Cory Kasimov at JPMorgan Chase & Co.
8/1/2017	Piper Jaffray Companies	Reiterated Rating	Overweight	$557.00	High	i Rating by Edward Tenthoff at Piper Jaffray Companies
8/1/2017	Robert W. Baird	Downgrade	Neutral ➝ Underperform	$408.00	High	i
7/31/2017	BMO Capital Markets	Reiterated Rating	Market Perform	$484.00	High	i Rating by Matthew Luchini at BMO Capital Markets
7/28/2017	Canaccord Genuity	Set Price Target	Buy ➝ Buy	$484.00 ➝ $522.00	Low	i Rating by John Newman at Canaccord Genuity
7/22/2017	Barclays	Reiterated Rating	Equal Weight	$400.00 ➝ $450.00	Low	i
7/21/2017	BMO Capital Markets	Reiterated Rating	Market Perform	$421.00 ➝ $484.00	Low	i Rating by Matthew Luchini at BMO Capital Markets
7/21/2017	Bank of America	Reiterated Rating	Buy	$589.00 ➝ $593.00	Low	i
7/14/2017	Credit Suisse Group	Downgrade	Hold	$485.00	Low	i Rating by Alethia Young at Credit Suisse Group AG
7/10/2017	Morgan Stanley	Reiterated Rating	Equal Weight	$405.00 ➝ $450.00	Medium	i
6/30/2017	BTIG Research	Reiterated Rating	Buy ➝ Buy	$480.00 ➝ $540.00	High	i
6/28/2017	SVB Leerink	Reiterated Rating	Outperform	$493.00 ➝ $573.00	Low	i Rating by Geoff Porges at SVB Leerink LLC
6/26/2017	Sanford C. Bernstein	Downgrade	Outperform ➝ Market Perform	$410.00 ➝ $480.00	Low	i
6/22/2017	SVB Leerink	Reiterated Rating	Outperform ➝ Outperform	$573.00	Medium	i Rating by Geoff Porges at SVB Leerink LLC
6/22/2017	Raymond James	Reiterated Rating	Outperform	$475.00 ➝ $547.00	Medium	i
6/21/2017	BMO Capital Markets	Reiterated Rating	Market Perform	$421.00	Low	i Rating by Matthew Luchini at BMO Capital Markets
6/20/2017	Canaccord Genuity	Set Price Target	Buy	$484.00	Low	i Rating by John Newman at Canaccord Genuity
6/20/2017	Piper Jaffray Companies	Boost Price Target	Overweight ➝ Overweight	$446.00 ➝ $557.00	Low	i Rating by Edward Tenthoff at Piper Jaffray Companies
6/14/2017	Oppenheimer	Reiterated Rating	Hold		Low	i Rating by Hartaj Singh at Oppenheimer Holdings Inc.
6/13/2017	SVB Leerink	Reiterated Rating	Outperform	$493.00	Low	i Rating by Geoff Porges at SVB Leerink LLC
5/25/2017	Sanford C. Bernstein	Reiterated Rating	Outperform		High	i
5/15/2017	Credit Suisse Group	Reiterated Rating	Buy	$485.00	Low	i Rating by Alethia Young at Credit Suisse Group AG
5/15/2017	Cowen	Reiterated Rating	Hold	$380.00	Low	i Rating by Phil Nadeau at Cowen Inc
5/15/2017	BMO Capital Markets	Boost Price Target	Hold	$412.00 ➝ $421.00	Low	i Rating by Matthew Luchini at BMO Capital Markets
5/8/2017	Barclays	Boost Price Target	Equal Weight	$375.00 ➝ $400.00	Low	i
5/5/2017	Credit Suisse Group	Reiterated Rating	Buy	$485.00	Low	i Rating by Alethia Young at Credit Suisse Group AG
5/5/2017	UBS Group	Set Price Target	Buy	$446.00 ➝ $489.00	N/A	i Rating by Carter Gould at UBS Group AG
5/5/2017	Canaccord Genuity	Upgrade	Hold ➝ Buy	$375.00 ➝ $484.00	Low	i Rating by John Newman at Canaccord Genuity
5/5/2017	Cowen	Reiterated Rating	Hold	$380.00	Low	i Rating by Phil Nadeau at Cowen Inc
5/5/2017	BMO Capital Markets	Reiterated Rating	Hold	$412.00 ➝ $421.00	Low	i Rating by Matthew Luchini at BMO Capital Markets
5/4/2017	Oppenheimer	Reiterated Rating	Hold		Low	i Rating by Hartaj Singh at Oppenheimer Holdings Inc.
4/12/2017	Jefferies Financial Group	Reiterated Rating	Hold	$357.00	Low	i
3/30/2017	Canaccord Genuity	Reiterated Rating	Hold	$375.00	Low	i Rating by John Newman at Canaccord Genuity
3/29/2017	BTIG Research	Reiterated Rating	Buy	$460.00	Medium	i
3/29/2017	UBS Group	Boost Price Target	Buy ➝ Buy	$435.00 ➝ $446.00	N/A	i Rating by Carter Gould at UBS Group AG
3/28/2017	BMO Capital Markets	Reiterated Rating	Hold	$408.00 ➝ $412.00	Low	i Rating by Matthew Luchini at BMO Capital Markets
3/28/2017	SVB Leerink	Set Price Target	Buy	$448.00	Low	i Rating by Geoff Porges at SVB Leerink LLC
3/28/2017	Robert W. Baird	Reiterated Rating	Neutral	$369.00	Low	i
3/20/2017	SVB Leerink	Reiterated Rating	Outperform		High	i Rating by Geoff Porges at SVB Leerink LLC
3/20/2017	BTIG Research	Reiterated Rating	Buy	$460.00	Low	i
3/17/2017	Canaccord Genuity	Reiterated Rating	Hold	$375.00	Low	i Rating by John Newman at Canaccord Genuity
3/17/2017	CIBC	Initiated Coverage	Market Perform ➝ Market Perform		Low	i
3/16/2017	Oppenheimer	Initiated Coverage	Hold		High	i Rating by Hartaj Singh at Oppenheimer Holdings Inc.
3/9/2017	UBS Group	Initiated Coverage	Buy ➝ Buy	$435.00	N/A	i
3/8/2017	Piper Jaffray Companies	Set Price Target	Buy	$446.00	Low	i Rating by Edward Tenthoff at Piper Jaffray Companies
2/16/2017	The Goldman Sachs Group	Downgrade	Buy ➝ Neutral		N/A	i
2/16/2017	Sanford C. Bernstein	Reiterated Rating	Outperform	$420.00 ➝ $410.00	N/A	i
2/13/2017	Piper Jaffray Companies	Upgrade	Neutral ➝ Overweight	$359.87 ➝ $446.00	N/A	i Rating by Edward Tenthoff at Piper Jaffray Companies
2/11/2017	SVB Leerink	Set Price Target	Buy	$448.00	N/A	i Rating by Geoff Porges at SVB Leerink LLC
2/10/2017	Canaccord Genuity	Reiterated Rating	Hold	$450.00	N/A	i Rating by John Newman at Canaccord Genuity
2/10/2017	Morgan Stanley	Lower Price Target	Equal Weight	$370.00 ➝ $367.00	N/A	i Rating by Matthew Harrison at Morgan Stanley
2/10/2017	Citigroup	Reiterated Rating	Buy	$420.00	N/A	i
2/10/2017	Sanford C. Bernstein	Lower Price Target		$410.00	N/A	i
2/10/2017	Credit Suisse Group	Reiterated Rating	Buy	$485.00	N/A	i Rating by Alethia Young at Credit Suisse Group AG
2/9/2017	Cowen	Set Price Target	Hold	$380.00	N/A	i Rating by Phil Nadeau at Cowen Inc
2/6/2017	The Goldman Sachs Group	Lower Price Target	Buy	$448.00 ➝ $446.00	N/A	i
2/3/2017	Canaccord Genuity	Set Price Target	Hold	$450.00	N/A	i Rating by John Newman at Canaccord Genuity
1/22/2017	JPMorgan Chase & Co.	Set Price Target	Hold	$440.00	N/A	i Rating by Cory Kasimov at JPMorgan Chase & Co.
1/11/2017	Cowen	Reiterated Rating	Market Perform	$400.00 ➝ $380.00	N/A	i Rating by Phil Nadeau at Cowen Inc
1/10/2017	SVB Leerink	Reiterated Rating	Outperform		N/A	i Rating by Geoff Porges at SVB Leerink LLC
1/10/2017	Wells Fargo & Company	Reiterated Rating	Market Perform		N/A	i
1/9/2017	Morgan Stanley	Set Price Target	Hold	$420.00 ➝ $370.00	N/A	i Rating by Matthew Harrison at Morgan Stanley
1/8/2017	Evercore ISI	Set Price Target	Hold	$421.00	N/A	i Rating by John Scotti at Evercore ISI
1/8/2017	Robert W. Baird	Reiterated Rating	Neutral	$379.00 ➝ $369.00	N/A	i
1/8/2017	BTIG Research	Reiterated Rating	Buy	$460.00	N/A	i
1/6/2017	Royal Bank of Canada	Reiterated Rating	Outperform	$626.00 ➝ $598.00	N/A	i Rating by Adnan Butt at Royal Bank of Canada
1/6/2017	Royal Bank of Canada	Lower Price Target	Outperform	$626.00 ➝ $598.00	N/A	i
1/6/2017	Chardan Capital	Lower Price Target	Neutral	$350.00 ➝ $345.00	N/A	i Rating by Gbola Amusa at Chardan Capital
12/28/2016	Argus	Reiterated Rating	Buy	$450.00	N/A	i
12/20/2016	SVB Leerink	Set Price Target	Buy	$492.00	N/A	i Rating by Geoff Porges at SVB Leerink LLC
12/20/2016	BMO Capital Markets	Initiated Coverage	Market Perform	$419.00	N/A	i
12/20/2016	Credit Suisse Group	Upgrade	Neutral ➝ Outperform	$481.00 ➝ $485.00	N/A	i
12/16/2016	BTIG Research	Upgrade	Neutral ➝ Buy	$460.00	N/A	i
12/12/2016	Canaccord Genuity	Set Price Target	Hold	$450.00	N/A	i Rating by John Newman at Canaccord Genuity
12/12/2016	Robert W. Baird	Reiterated Rating	Positive	$379.00	N/A	i
12/12/2016	Chardan Capital	Upgrade	Sell ➝ Neutral	$300.00 ➝ $350.00	N/A	i Rating by Gbola Amusa MD CFA at Chardan Capital
12/5/2016	Royal Bank of Canada	Set Price Target	Buy	$626.00	N/A	i Rating by Adnan Butt at Royal Bank of Canada
12/1/2016	SVB Leerink	Set Price Target	Buy	$500.00	N/A	i Rating by Geoff Porges at SVB Leerink LLC
11/17/2016	BTIG Research	Reiterated Rating	Neutral		N/A	i
11/17/2016	Jefferies Financial Group	Reiterated Rating	Hold	$394.00	N/A	i
11/7/2016	Robert W. Baird	Reiterated Rating	Neutral	$448.00 ➝ $379.00	N/A	i Rating by Brian Skorney at Robert W. Baird
11/7/2016	Chardan Capital	Lower Price Target	Sell	$325.00 ➝ $300.00	N/A	i Rating by Gbola Amusa MD CFA at Chardan Capital
11/6/2016	Canaccord Genuity	Set Price Target	Hold	$450.00	N/A	i Rating by John Newman at Canaccord Genuity
11/6/2016	Cowen	Set Price Target	Hold	$430.00	N/A	i Rating by Phil Nadeau at Cowen Inc
11/6/2016	JPMorgan Chase & Co.	Set Price Target	Hold	$440.00	N/A	i Rating by Cory Kasimov at JPMorgan Chase & Co.
10/30/2016	JPMorgan Chase & Co.	Set Price Target	Hold	$477.00	N/A	i Rating by Cory Kasimov at JPMorgan Chase & Co.
10/30/2016	Cowen	Set Price Target	Hold	$430.00	N/A	i Rating by Phil Nadeau at Cowen Inc
10/30/2016	Piper Jaffray Companies	Set Price Target	Hold	$447.00	N/A	i Rating by Edward Tenthoff at Piper Jaffray Companies
10/28/2016	Roth Capital	Set Price Target	Buy	$520.00	N/A	i Rating by Joseph Pantginis at Roth Capital
10/25/2016	SVB Leerink	Set Price Target	Buy	$513.00	N/A	i Rating by Geoff Porges at SVB Leerink LLC
10/13/2016	Piper Jaffray Companies	Set Price Target	Hold	$447.00	N/A	i Rating by Edward Tenthoff at Piper Jaffray Companies
10/12/2016	Roth Capital	Reiterated Rating	Buy	$520.00	N/A	i
10/4/2016	Roth Capital	Reiterated Rating	Buy	$520.00	N/A	i
10/4/2016	Royal Bank of Canada	Reiterated Rating	Outperform	$648.00	N/A	i Rating by adnan butt at Royal Bank of Canada
10/4/2016	Robert W. Baird	Reiterated Rating	Neutral	$448.00	N/A	i Rating by Brian Skorney at Robert W. Baird
10/3/2016	SVB Leerink	Set Price Target	Buy	$530.00	N/A	i Rating by geoff porges at SVB Leerink LLC
9/30/2016	Canaccord Genuity	Reiterated Rating	Hold	$450.00	N/A	i Rating by John Newman at Canaccord Genuity
9/30/2016	Chardan Capital	Reiterated Rating	Sell	$325.00	N/A	i Rating by Gbola Amusa MD CFA at Chardan Capital
9/27/2016	The Goldman Sachs Group	Reiterated Rating	Buy	$521.00	N/A	i
9/23/2016	Roth Capital	Reiterated Rating	Buy	$520.00	N/A	i Rating by Joseph Pantginis at Roth Capital
9/23/2016	Robert W. Baird	Reiterated Rating	Neutral	$448.00	N/A	i Rating by Brian Skorney at Robert W. Baird
9/21/2016	SVB Leerink	Reiterated Rating	Buy	$530.00	N/A	i Rating by geoff porges at SVB Leerink LLC
9/20/2016	Piper Jaffray Companies	Reiterated Rating	Hold	$447.00	N/A	i Rating by Edward Tenthoff at Piper Jaffray Companies
9/9/2016	Piper Jaffray Companies	Reiterated Rating	Neutral	$447.00	N/A	i Rating by Edward Tenthoff at Piper Jaffray Companies
8/17/2016	Jefferies Financial Group	Reiterated Rating	Hold		N/A	i Rating by Biren Amin at Jefferies Financial Group Inc.
8/10/2016	The Goldman Sachs Group	Reiterated Rating	Buy		N/A	i
8/6/2016	SVB Leerink	Set Price Target	Buy	$530.00 ➝ $511.00	N/A	i Rating by geoff porges at SVB Leerink LLC
8/6/2016	Royal Bank of Canada	Reiterated Rating	Buy		N/A	i Rating by adnan butt at Royal Bank of Canada
8/5/2016	Roth Capital	Reiterated Rating	Buy	$520.00	N/A	i Rating by Joseph Pantginis at Roth Capital
8/5/2016	Brean Capital	Reiterated Rating	Buy	$489.00	N/A	i Rating by Jason Wittes at Brean Capital
8/5/2016	Canaccord Genuity	Reiterated Rating	Hold	$450.00	N/A	i Rating by John Newman at Canaccord Genuity
8/5/2016	Robert W. Baird	Downgrade	Outperform ➝ Neutral	$505.00 ➝ $448.00	N/A	i Rating by Brian Skorney at Robert W. Baird
8/5/2016	Cowen	Reiterated Rating	Hold	$430.00	N/A	i Rating by Phil Nadeau at Cowen Inc
7/19/2016	SVB Leerink	Reiterated Rating	Buy		N/A	i Rating by Geoff Porges at SVB Leerink LLC
7/12/2016	BTIG Research	Reiterated Rating	Hold		N/A	i
7/11/2016	SVB Leerink	Reiterated Rating	Buy		N/A	i Rating by Geoff Porges at SVB Leerink LLC
6/30/2016	Sanford C. Bernstein	Reiterated Rating	Buy		N/A	i Rating by Ronny Gal at Sanford C. Bernstein
6/29/2016	Sanford C. Bernstein	Initiated Coverage	Outperform	$400.00	N/A	i
6/23/2016	Citigroup	Reiterated Rating	Buy	$470.00	N/A	i Rating by Robyn Karnauskas at Citigroup Inc.
6/17/2016	Canaccord Genuity	Reiterated Rating	Hold	$450.00	N/A	i Rating by Reiterated, Today Hold at Canaccord Genuity

(Data available from 6/16/2016 forward)

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis in adults, and asthma in adults and adolescents; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; and Kevzara solution for subcutaneous injection for treating rheumatoid arthritis in adults. In addition, the company offers Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer. Further, it offers Inmazeb injection for infection caused by Zaire ebolavirus; and develops product candidates for treating patients with eye, allergic and inflammatory, cancer, cardiovascular and metabolic, pain, infectious, and other diseases. The company has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services. It has collaborations with Zai Lab Limited; Intellia Therapeutics, Inc.; and Biomedical Advanced Research Development Authority. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York.

Today's Range

Now: $523.58

$522.24

$542.42

50 Day Range

MA: $501.69

$472.80

$532.04

52 Week Range

Now: $523.58

$441.00

$664.64

Volume

912,555 shs

Average Volume

922,338 shs

Market Capitalization

$55.78 billion

P/E Ratio

14.82

Dividend Yield

N/A

Beta

0.2

Frequently Asked Questions

What sell-side analysts currently cover shares of Regeneron Pharmaceuticals?

The following equities research analysts have issued stock ratings on Regeneron Pharmaceuticals in the last year: Barclays PLC, Benchmark Co., BMO Capital Markets, Canaccord Genuity, Cantor Fitzgerald, Citigroup Inc., Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell, Cowen Inc, Credit Suisse Group AG, FIX, JPMorgan Chase & Co., Morgan Stanley, Oppenheimer Holdings Inc., Piper Sandler, Robert W. Baird, Smith Barney Citigroup, SunTrust Banks, Inc., SVB Leerink LLC, The Goldman Sachs Group, Inc., and Truist.
View the latest analyst ratings for REGN.

What is the current price target for Regeneron Pharmaceuticals?

18 Wall Street analysts have set twelve-month price targets for Regeneron Pharmaceuticals in the last year. Their average twelve-month price target is $656.11, suggesting a possible upside of 24.7%. The Goldman Sachs Group, Inc. has the highest price target set, predicting REGN will reach $800.00 in the next twelve months. Morgan Stanley has the lowest price target set, forecasting a price of $495.00 for Regeneron Pharmaceuticals in the next year.
View the latest price targets for REGN.

What is the current consensus analyst rating for Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals currently has 4 hold ratings and 12 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe REGN will outperform the market and that investors should add to their positions of Regeneron Pharmaceuticals.
View the latest ratings for REGN.

What other companies compete with Regeneron Pharmaceuticals?

Other companies that are similar to Regeneron Pharmaceuticals include Amgen, Gilead Sciences, Biogen, Vertex Pharmaceuticals, Alexion Pharmaceuticals, Seagen, Exact Sciences, Alnylam Pharmaceuticals, Incyte, BioMarin Pharmaceutical, Novavax, Repligen, Neurocrine Biosciences, United Therapeutics and Exelixis.

How do I contact Regeneron Pharmaceuticals' investor relations team?

Regeneron Pharmaceuticals' physical mailing address is 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY, 10591. The biopharmaceutical company's listed phone number is 914-847-7000 and its investor relations email address is [email protected] The official website for Regeneron Pharmaceuticals is www.regeneron.com.